Inclisiran Therapy for Hyperlipemia

Patient Eligibility and Clinical Profile

• The American Diabetes Association recommends considering non-statin therapies for patients with statin intolerance, which is a recognized contraindication to statin therapy, as seen in patients with documented statin myopathy and nonalcoholic fatty liver disease 1, 2
• Patients with familial hyperlipemia who have failed prior treatment with alternative lipid-lowering therapies, such as Vascepa, may be eligible for inclisiran therapy 1

Efficacy and Clinical Benefit

• The American College of Cardiology guidelines support the use of inclisiran, which has demonstrated a mean placebo-corrected reduction in LDL-C of 50.7% at day 510 in phase 3 trials (ORION-9, ORION-10, ORION-11) 3, 4
• The time-adjusted mean reduction in LDL-C was 50.5%, indicating sustained efficacy of inclisiran therapy 5

Safety Profile and Appropriateness

• Inclisiran has demonstrated a favorable safety profile in clinical trials, with most common adverse events including injection site reactions, arthralgia, and bronchitis 3, 5
• The 2022 ACC Expert Consensus Decision Pathway recommends inclisiran as an option for non-statin therapy in patients who cannot tolerate statins, such as those with statin myopathy and nonalcoholic fatty liver disease 6
• The twice-yearly maintenance dosing regimen of inclisiran is beneficial for adherence in patients with limited therapeutic options 5, 7

Addressing Coverage Criteria

• Patients with significantly elevated LDL-C levels (exceeding 100 mg/dL) and documented contraindication to statin therapy may meet coverage criteria for inclisiran therapy 6, 1

Leqvio (Inclisiran) for Mixed Hyperlipidemia Treatment

Clinical Guidelines and Recommendations

• The International Lipid Expert Panel acknowledges improved access to inclisiran in many countries for treating primary hypercholesterolemia and mixed dyslipidemia 8
• The American College of Cardiology, American Heart Association, American College of Emergency Physicians, National Association of EMS Physicians, and Society for Cardiovascular Angiography and Interventions guideline includes inclisiran among non-statin LDL-lowering therapies that can be added when LDL-C goals are not met with statin therapy alone 9

Inclisiran Treatment Duration

Dosing Schedule and Administration

• The American College of Cardiology recommends the dosage of inclisiran (Leqvio) as 284 mg administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months thereafter 10

Duration of Effect and Efficacy

• Inclisiran demonstrated a mean placebo-corrected reduction in LDL-C of 50.7% at day 510, with a time-adjusted mean reduction of 50.5% 10

Long-term Safety Profile

• The American College of Cardiology reports that safety data from clinical trials supports the long-term use of inclisiran with a favorable safety profile similar to placebo 10
• The most common adverse effects of inclisiran are injection site reactions (5.0% vs 0.7% for placebo), which are predominantly mild and not persistent 10

Ongoing Cardiovascular Outcomes Trials

• Two cardiovascular outcomes trials, ORION-4 and VICTORION-2P, are currently in progress to determine the effect of inclisiran on cardiovascular morbidity and mortality 10
• ORION-4 is following approximately 15,000 participants for a planned median duration of about 5 years 10

Inclisiran for Hyperlipidemia: Efficacy and Medical Necessity

Guideline-Supported Indications

• The 2024 International Lipid Expert Panel explicitly endorses inclisiran for ASCVD patients failing to reach LDL-C goals on statin therapy, with a recommended sequence of maximally tolerated statin therapy, addition of ezetimibe, and then PCSK9 inhibitor (including inclisiran) if LDL-C goal not achieved 11
• The American College of Cardiology recommends inclisiran as a non-statin option when LDL-C goals are not met with statin therapy alone, although this specific recommendation is not directly cited, the International Lipid Expert Panel provides similar guidance 11

Evidence of Efficacy

• The VICTORION-Initiate study showed an "inclisiran first" strategy achieved LDL-C <70 mg/dL in 81.8% of patients versus 22.2% with usual care (p<0.001), demonstrating the efficacy of inclisiran in reducing LDL-C levels 11
• Exploratory analyses from ORION 9-11 studies demonstrated significant reduction in composite major adverse cardiovascular events (OR 0.74; 95% CI 0.58-0.94), providing evidence for the cardiovascular benefits of inclisiran 11

Treatment Algorithm Position

• The 2024 International Lipid Expert Panel recommends inclisiran as a PCSK9 inhibitor option if LDL-C goal not achieved despite maximally tolerated statin plus ezetimibe (Class I), and inclisiran can be initiated immediately upon failure to reach LDL-C <70 mg/dL on maximally tolerated statin 11

Reimbursement and Access Considerations

• Inclisiran is available in most European countries with varying reimbursement structures, and coverage criteria typically require documented failure to achieve LDL-C goals on maximally tolerated statin therapy 11

Inclisiran Therapy for Hyperlipidemia

Patient Selection and Monitoring

• The American College of Cardiology recommends inclisiran for patients who fail to reach LDL-C goals on maximally tolerated statin therapy, with or without ezetimibe, and have measurable LDL-C values 12
• The International Lipid Expert Panel suggests inclisiran for treating primary hypercholesterolemia and mixed dyslipidemia, but emphasizes the need for LDL-C goals to be achieved before initiation 12

Treatment Outcomes and Efficacy

• Inclisiran has been shown to reduce LDL-C by a mean of 50.7% at day 510 in trials, but requires measurable LDL-C values to assess response 12
• The FDA label states that the LDL-lowering effect of inclisiran may be measured as early as 30 days after initiation, and recommends assessing LDL-C when clinically indicated 12

Triglyceride Management

• Aggressive triglyceride-lowering therapy, such as high-dose omega-3 fatty acids, fibrates, or niacin, may be necessary to control severe hypertriglyceridemia before initiating inclisiran 12
• Inclisiran has no effect on triglycerides, and its use should be guided by LDL-C reduction, not triglyceride levels 12